AR092045A1 - Combinaciones farmaceuticas - Google Patents

Combinaciones farmaceuticas

Info

Publication number
AR092045A1
AR092045A1 ARP130102776A ARP130102776A AR092045A1 AR 092045 A1 AR092045 A1 AR 092045A1 AR P130102776 A ARP130102776 A AR P130102776A AR P130102776 A ARP130102776 A AR P130102776A AR 092045 A1 AR092045 A1 AR 092045A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
substituents
deuterium
fluorine
Prior art date
Application number
ARP130102776A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR092045A1 publication Critical patent/AR092045A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP130102776A 2012-08-07 2013-08-05 Combinaciones farmaceuticas AR092045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07

Publications (1)

Publication Number Publication Date
AR092045A1 true AR092045A1 (es) 2015-03-18

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102776A AR092045A1 (es) 2012-08-07 2013-08-05 Combinaciones farmaceuticas

Country Status (39)

Country Link
US (1) US9474754B2 (cg-RX-API-DMAC7.html)
EP (2) EP3574904A1 (cg-RX-API-DMAC7.html)
JP (3) JP6342396B2 (cg-RX-API-DMAC7.html)
KR (1) KR102112885B1 (cg-RX-API-DMAC7.html)
CN (1) CN104519887B (cg-RX-API-DMAC7.html)
AR (1) AR092045A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013299841B8 (cg-RX-API-DMAC7.html)
CA (1) CA2879548C (cg-RX-API-DMAC7.html)
CL (1) CL2015000294A1 (cg-RX-API-DMAC7.html)
CO (1) CO7200273A2 (cg-RX-API-DMAC7.html)
CY (1) CY1122143T1 (cg-RX-API-DMAC7.html)
DK (1) DK2882440T3 (cg-RX-API-DMAC7.html)
EA (1) EA028420B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15008695A (cg-RX-API-DMAC7.html)
ES (1) ES2717911T3 (cg-RX-API-DMAC7.html)
GT (1) GT201500025A (cg-RX-API-DMAC7.html)
HK (1) HK1211831A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20190537T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042877T2 (cg-RX-API-DMAC7.html)
IL (1) IL236934B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00450A (cg-RX-API-DMAC7.html)
JO (1) JOP20130236B1 (cg-RX-API-DMAC7.html)
LT (1) LT2882440T (cg-RX-API-DMAC7.html)
MA (1) MA37829A1 (cg-RX-API-DMAC7.html)
MX (1) MX359403B (cg-RX-API-DMAC7.html)
MY (1) MY176031A (cg-RX-API-DMAC7.html)
NZ (1) NZ703940A (cg-RX-API-DMAC7.html)
PE (2) PE20150673A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500246B1 (cg-RX-API-DMAC7.html)
PL (1) PL2882440T3 (cg-RX-API-DMAC7.html)
PT (1) PT2882440T (cg-RX-API-DMAC7.html)
RS (1) RS58734B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201500321YA (cg-RX-API-DMAC7.html)
SI (1) SI2882440T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000027A1 (cg-RX-API-DMAC7.html)
TR (1) TR201904980T4 (cg-RX-API-DMAC7.html)
TW (1) TWI607754B (cg-RX-API-DMAC7.html)
UA (1) UA115786C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014025688A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013299841B8 (en) * 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
US10328065B2 (en) 2015-08-28 2019-06-25 Novartis Ag Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017210538A1 (en) * 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
WO2019026007A1 (en) * 2017-08-03 2019-02-07 Novartis Ag THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
JPWO2023145530A1 (cg-RX-API-DMAC7.html) * 2022-01-27 2023-08-03
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
CN120359031A (zh) * 2022-09-26 2025-07-22 马布可尔公司 用于治疗癌症的b-raf抑制剂和抗egfr抗体的组合
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AU2010289794B2 (en) * 2009-08-24 2014-10-02 Genentech, Inc. Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
JP2013507442A (ja) * 2009-10-12 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
TR201802943T4 (tr) * 2010-11-08 2018-03-21 Novartis Ag (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.
WO2013070998A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
CA2855243C (en) * 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
AU2013299841B8 (en) * 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor

Also Published As

Publication number Publication date
AU2013299841A8 (en) 2017-01-05
PL2882440T3 (pl) 2019-07-31
GT201500025A (es) 2017-09-28
LT2882440T (lt) 2019-04-25
UA115786C2 (uk) 2017-12-26
TN2015000027A1 (en) 2016-06-29
TWI607754B (zh) 2017-12-11
CN104519887B (zh) 2017-06-27
ES2717911T3 (es) 2019-06-26
CA2879548C (en) 2020-07-21
EA201590332A1 (ru) 2015-06-30
IL236934B (en) 2018-11-29
JP2018109022A (ja) 2018-07-12
JP6974669B2 (ja) 2021-12-01
PT2882440T (pt) 2019-04-23
CO7200273A2 (es) 2015-02-27
MY176031A (en) 2020-07-22
US9474754B2 (en) 2016-10-25
CY1122143T1 (el) 2020-11-25
DK2882440T3 (da) 2019-05-06
MX2015001732A (es) 2015-06-03
JP2020019780A (ja) 2020-02-06
RS58734B1 (sr) 2019-06-28
EP2882440B1 (en) 2019-02-27
AU2013299841A1 (en) 2015-02-12
US20150265616A1 (en) 2015-09-24
SI2882440T1 (sl) 2019-05-31
MX359403B (es) 2018-09-26
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
ECSP15008695A (es) 2019-03-29
JP2015524472A (ja) 2015-08-24
PE20191655A1 (es) 2019-11-07
PH12015500246A1 (en) 2015-03-30
JP6595024B2 (ja) 2019-10-23
AU2013299841B2 (en) 2016-11-24
PH12015500246B1 (en) 2015-03-30
AU2013299841B8 (en) 2017-01-05
HK1204976A1 (en) 2015-12-11
IN2015DN00450A (cg-RX-API-DMAC7.html) 2015-06-26
JOP20130236B1 (ar) 2021-08-17
EP2882440A1 (en) 2015-06-17
TR201904980T4 (tr) 2019-05-21
BR112015002384A2 (pt) 2017-07-04
KR102112885B1 (ko) 2020-05-19
JP6342396B2 (ja) 2018-06-13
PE20150673A1 (es) 2015-05-20
MA37829A1 (fr) 2017-01-31
NZ703940A (en) 2018-04-27
BR112015002384A8 (pt) 2023-01-31
CL2015000294A1 (es) 2015-05-08
CN104519887A (zh) 2015-04-15
WO2014025688A1 (en) 2014-02-13
HRP20190537T1 (hr) 2019-06-28
TW201410247A (zh) 2014-03-16
SG11201500321YA (en) 2015-04-29
KR20150040905A (ko) 2015-04-15
HUE042877T2 (hu) 2019-07-29
EA028420B1 (ru) 2017-11-30
HK1211831A1 (zh) 2016-06-03

Similar Documents

Publication Publication Date Title
AR092045A1 (es) Combinaciones farmaceuticas
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
AR093408A1 (es) Derivados de oxazolidin-2-ona-pirimidina
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
AR073369A1 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
AR097862A1 (es) Inhibidores de tirosina quinasa de bruton
EA201491671A1 (ru) Гетероциклильные соединения
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
AR086481A1 (es) COMBINACION DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K), Y UN INHIBIDOR DE mTOR
EA201790661A3 (ru) Ингибиторы вируса гепатита c
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
PE20160540A1 (es) Inhibidores de bromodominios
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
EA201591195A1 (ru) Новые хинолоновые производные
PE20160550A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
PE20160194A1 (es) Composiciones y metodos para tratar anemia

Legal Events

Date Code Title Description
FC Refusal